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prediction of atrial fibrillation recurrence
after pulmonary vein isolation: a
cardiovascular magnetic resonance study
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Abstract
Background: The relationship between pulmonary vein (PV) anatomy and successful catheter ablation of atrial
fibrillation (AF) is poorly understood
Methods: First-pass contrast enhanced PV magnetic resonance angiography was performed in 71 consecutive
patients prior to PV isolation. PV diameter and cross-sectional area (CSA) were measured prior to PV isolation. Any
symptomatic or asymptomatic AF >10s was considered a recurrence. Early recurrence was defined as recurrent AF
≤30 days after PV isolation, while late recurrence of AF was defined as recurrent AF >30 days after.
Results: At 1 year, 57 % had any recurrence of AF while 41 % had late recurrence of AF. Study subjects with one or
more PV diameter in the top 10th percentile had trend toward more early recurrent AF (HR 1.99, p = 0.053). Study
subjects with one or more PV CSA in the top 10th percentile had more late recurrent AF (HR 2.25, p = 0.039) and a
trend toward more early recurrent AF (HR 1.94, p = 0.064). With multivariate analysis, PV size was not associated
with early recurrent AF, but late recurrent AF was associated with one or more large PV, increased left atrial size,
and non-paroxysmal AF. Study subjects with all three of these risk factors had a 100 % rate of late recurrent AF at
1 year, while those with none had a 7 % rate of late recurrent AF.
Conclusions: Larger PV size is independently associated with more late recurrent AF after PV isolation.
Determination of PV size prior to PV isolation may predict procedural success.
Keywords: Atrial fibrillation, Catheter ablation, Cardiovascular magnetic resonance, Pulmonary vein
Background
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia [1]. The recognition that the pul-
monary veins (PV) have a critical role in the develop-
ment and maintenance of AF has led to the development
of several procedures to electrically isolate the PV from the
left atrium to prevent recurrent AF [2–7]. The cause of re-
current AF is incompletely understood but is associated
with electrical reconnection of the PV with the left atrium
[8, 9]. The extent to which anatomic measurements of the
PV might predict electrical reconnection has not been
investigated.
We hypothesized that patients with large PV would be
at higher risk for electrical reconnection and thus more
recurrent AF after PV isolation. We evaluated this hy-
pothesis in a consecutive series of 71 patients who
underwent PV magnetic resonance angiography (MRA)
prior to PV isolation.
Methods
Study cohort
The study cohort was comprised of a consecutive series
of 71 patients who underwent cardiovascular magnetic
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resonance (CMR) prior to PV isolation for the treatment
of AF. The clinical characteristics of the study cohort are
summarized in Table 1. Antiarrhythmic drug therapy
had failed in 58 (72 %) after the use of 1 (29 [41 %]), 2
(19 [27 %]), or 3 or more (10 [14 %]) drugs. The study
was approved by the hospital Committee on Clinical In-
vestigations (Institutional Review Board), with waiver of
written informed consent.
CMR Technique
CMR was performed using a 1.5 T whole-body MR system
(Intera, Philips Medical Systems, Best, The Netherlands)
with a five-element cardiac synergy coil for radiofrequency
signal reception.
First pass breath-hold 3D contrast enhanced MRA
of the PV was obtained after manual bolus adminis-
tration of 0.2 mmol/kg gadopentetate dimeglumine
(Magnevist ®, Berlex Laboratories, Wayne, NJ), imme-
diately followed by a saline flush. Data acquisition
began after a delay determined by a small timing bolus
given prior to contrast enhanced MRA. A spoiled end-
expiratory breath-hold 3D gradient echo sequence with
the following parameters was used: repetition time 3.6 ms,
echo time 1.1 ms, flip angle 30 degrees, 50 slices, slice
thickness 4 mm interpolated to 2 mm, field of view
480 mm, matrix 272 × 512, imaging time 22 s. The 3D
volume was centered on the left atrium and included
all PV. Images were prospectively acquired in the axial
plane. Commercially available system software (EasyVi-
sion 5.1 or ViewForum R5.1, Philips Medical Systems,
Best, The Netherlands) was used to generate multipla-
nar reformations.
Steady-state free-precession breath-hold gradient echo
ECG-gated cine CMR was performed in the 4-chamber
and contiguous short axis orientations during a series of
end-tidal breath-holds. Short axis images were acquired
from the left ventricular base to the apex with 10 mm
slices and no gap. The following parameters were used:
repetition time 3.0 ms, echo time 1.5 ms, flip angle 60 °,
field of view 480 mm, matrix 208 × 256.
Table 1 Characteristics of the study cohort and hazard ratios for the recurrence of a trial fibrillation (AF)
Early Recurrent AF Late Recurrent AF
Characteristic HR (95 %) p HR (95 % CI) p
Demographics
Men 55 (77 %) 3.62 (1.10 – 11.88) 0.034 1.84 (0.64 – 5.32) 0.261
Age, years * 52 ± 11 1.27 (0.92 – 1.75) 0.147 1.01 (0.97 – 1.05) 0.621
Body surface area, m2 2.10 ± 0.22 0.68 (0.14-3.39) 0.634 0.36 (0.07 – 1.97) 0.237
Body mass index, kg/m2 29.3 ± 5.6 0.99 (0.93 – 1.06) 0.762 0.99 (0.92 – 1.06) 0.780
Type of atrial fibrillation
Paroxysmal 40 (56 %) 0.36 (0.18 – 0.73) 0.004 0.36 (0.17 – 0.80) 0.012
Persistent 25 (35 %)
Permanent 6 (8 %)
Medical history
Mitral regurgitation † 33 (46 %) 1.68 (0.85 – 3.35) 0.138 1.52 (0.71 – 3.25) 0.280
Hypertension 32 (45 %) 1.27 (0.64 – 2.52) 0.488 1.38 (0.64 – 2.95) 0.409
Obstructive sleep apnea 19 (27 %) 0.79 (0.35 – 1.74) 0.551 1.17 (0.51 – 2.68) 0.713
Diabetes mellitus 10 (14 %) 1.38 (0.57 – 3.36) 0.471 2.04 (0.86 – 4.83) 0.106
Coronary artery disease 7 (10 %) 1.27 (0.44 – 3.61) 0.659 1.54 (0.46 – 5.15) 0.489
Obstructive lung disease 3 (4 %) 0 (not defined) || 0.991 0 (not defined) || 0.991
No comorbidity 22 (31 %) 0.71 (0.32 – 1.58) 0.400 0.89 (0.38 – 2.12) 0.799
CMR measurements
LV ejection fraction, % * 61 ± 10 0.92 (0.66 – 1.28) 0.609 1.22 (0.79 –1.88) 0.371
LV end diastolic volume, ml * 163 ± 40 0.91 (0.82 – 1.01) 0.067 0.92 (0.82 – 1.04) 0.168
LV mass, g * 129 ± 34 1.03 (0.93 – 1.14) 0.611 0.96 (0.86 – 1.08) 0.516
Left atrial dimension (4-chamber), cm 5.7 ± 0.8 1.58 (0.99 – 2.51) 0.056 2.20 (1.38 – 3.49) <0.001
* The hazard ratio is reported for a 10 unit change
† Determined by the presence of ≥mild mitral regurgitation on echocardiography
|| No subjects with obstructive lung disease had a recurrence of AF
HR = hazard ratio, CI = confidence interval, LV = left ventricular
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Image Analysis
All measurements were made by an observer blinded to
the clinical treatment data using commercially available
system software (EasyVision 5.1, Philips Medical Sys-
tems, Best, The Netherlands). The maximum left atrial
dimension was measured in the 4-chamber orientation.
Left ventricular volumes, mass and ejection fraction
were determined using Simpson’s rule [10]. The PV were
measured at the location in the sagittal plane at which
the PV separate from the left atrium and from each
other identified by viewing a sagittal plane reconstruc-
tion of the dataset [11]. The maximal diameter and
cross-sectional area (CSA) of each PV were measured. A
left common PV was defined as a single left-sided PV
entering the left atrium as determined in the sagittal
plane. A right middle PV was defined as any right-sided
pulmonary vein identified in the sagittal plane in
addition to the right inferior and right superior PV.
Any PV with a diameter in the top 10th percentile of
all PV was defined as having a large diameter. Similarly,
any PV with a CSA in the top 10th percentile was de-
fined as having a large CSA. A separate analysis was per-
formed for each measure of PV size.
PV Isolation Procedure
The electrophysiology procedure was performed using a
femoral venous approach. A decapolar catheter was po-
sitioned in the coronary sinus and a second catheter was
placed in the right atrium. Left atrial access was ob-
tained by two transseptal punctures. Transesophageal or
intracardiac echocardiography was used to identify PV
anatomy and velocities before and after ablation, to iden-
tify catheter position with reference to the vein ostia, to
determine the presence or absence of pericardial effu-
sion, and in some cases to guide transseptal puncture.
Following transseptal puncture, patients received intra-
venous heparin to maintain a serum activated clotting
time >250 s.
Three-dimensional electroanatomic mapping of the
left atrium and PV was performed using a non-irrigated
4 or 8 mm tip NaviStar™ catheter (Biosense Webster)
and CARTO™ (Biosense Webster) and/or EnSite NavX™
(Endocardial Solutions) recording systems. Electrograms
were recorded during sinus rhythm, coronary sinus
pacing, or AF at the ostia of the PV with a 10–14 pole
circumferential catheter with distal ring configuration
(Biosense Webster or Bard). Radiofrequency ablation
was performed outside the PV ostium near sites with the
earliest PV electrograms. Ablation was performed for
20–60 s with a target temperature of 52 °C. Temperature
was considered adequate if it reached 45 °C. The process
was repeated until complete bi-directional electrical PV
isolation was achieved, defined by both entrance block
as demonstrated by loss of PV potentials, and exit block
demonstrated by failure to capture the left atrium during
sinus rhythm by pacing (at 10 mA and 2 ms pulse width)
each of the bipolar pairs of electrodes of the circumfer-
ential catheter positioned at the entrance of the PV. All
PV were routinely isolated for all patients.
After PV isolation, induction of AF was attempted by
burst pacing from the right atrium and coronary sinus
before and after administration of isoproterenol. Isola-
tion of the PV was reassessed and if reconnection was
observed the vein was re-isolated. Left atrial ablation
lines (mitral isthmus line and/or posterior left atrial line)
were performed in 16 (23 %) patients with inducible sus-
tained left atrial tachycardia. A right atrial isthmus line
(tricuspid valve to inferior vena cava) was performed in
17 (24 %) patients with a history of or inducible right
atrial isthmus dependent flutter.
Post ablation care and monitoring
Patients were treated with warfarin to achieve an inter-
national normalized ratio of 2.0 to 3.0 for at least
6 months after PV isolation, as well as acetylsalicylic
acid (325 mg/day) for at least 1 month. Antiarrhythmic
drugs were continued post procedure for patients with
a history of persistent or permanent AF, and were reini-
tiated in patients with early (<30 days) recurrences of
AF. Antiarrhythmic drugs were used in 29 (41 %)
patients post procedure, including 12 (29 %) free of AF
at last follow-up.
Evaluation of symptomatic or asymptomatic AF was
performed using both a 2 week transtelephonic event
recorder and 24 h Holter monitor at 1, 3, 6, and
12 months. Additional monitoring was done for patients
with symptoms. Recurrent AF was deemed present if an
asymptomatic or symptomatic atrial tachyarrhythmia
consistent with AF was documented to last >10 s. Early
recurrent AF was defined as any recurrent AF during
the first 30 days. Late recurrent AF was defined as recur-
rent AF after 30 days. The median duration of follow-up
was 442 days.
Statistical Methods
Continuous values are reported as the mean ± standard
deviation. Categorical values are reported as counts and
percentages. The occurrence of recurrent AF was esti-
mated using the product-limit (Kaplan-Meier) method.
The relationship between PV size and recurrent AF was
assessed using the product-limit method and the log
rank test. The relationship of PV size and clinical vari-
ables with recurrent AF was assessed using proportional
hazards regression. The proportional hazards assump-
tion was confirmed for all variables by examining log-log
survival curves. Multivariate analysis was performed
using proportional hazards regression with backward se-
lection of variables. Any variable with a p-value of ≤0.1
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was eligible for inclusion and retention in the model.
Hazard ratios (HR) are reported as the estimate with the
95 % confidence interval (CI). A p-value of <0.05 was
used for determination of statistical significance. All stat-
istical analysis was performed using SAS for Windows
(v9.3, SAS Institute, Cary, NC).
Results
The mean duration of the electrophysiological procedure
was 257 ± 63 min. The mean number of ablations per-
formed was 73 ± 25 with a mean total ablation time of
53 ± 23 min. There was no relationship between the pro-
cedure time, total number of ablations or total ablation
time with any measure of PV size or with the presence
of one or more large PV by any measurement criteria
(p >0.15 for all).
At 1 year of follow-up, 57 % had any recurrent AF and
41 % had late recurrence of AF (Fig. 1). The relationship
of the clinical characteristics of the cohort with the re-
currence of AF are shown in Table 1. There was no rela-
tionship of the performance of additional left or right
atrial ablation lines with the recurrence of AF (p >0.7
for both). Early recurrent AF was strongly associated
with late recurrent AF (HR 5.14 (95 % CI 2.06 – 12.80,
p <0.001).
Size measurements for all PV are shown in Table 2.
Data regarding the prognostic significance of PV size is
shown in Table 3. The relationship of PV size to recur-
rent AF was examined by evaluating the recurrence in
study subjects with one or more large PV as defined by
boundary values at the 95th, 90th, and 85th percentiles of
the individual PV measurements. The presence of one
or more large PV CSA was associated with both early
and late recurrence of AF, while the presence of one or
more large PV diameter was associated with early
recurrence of AF only. The optimal boundary value for
the diameter was the 90th percentile. The 95th and 90th
percentile boundary values for the CSA produced simi-
lar results for late recurrence of AF. Based on these re-
sults, we chose a boundary value of the 90th percentile
as the optimal measure to determine that a PV was
large. Using this criterion, 24 (34 %) patients had one
or more PV with a large diameter and 23 (32 %) had
one or more PV with a large CSA. Multiple large PV
were present in 2 patients with large diameter PV and 3
patients with large CSA PV. The distribution of large
PV is shown in Table 4. Left common and right super-
ior PV were most likely to have increased size while no
left superior or right middle PV were large.
The relationship between recurrent AF and the pres-
ence of one or more large CSA PV was further investi-
gated with multivariate proportional hazards regression
(Table 5). With simultaneous adjustment for male gen-
der, the presence of paroxysmal AF, and left ventricular
(LV) end diastolic volume, left atrial dimension and one
or more large PV CSA were no longer significantly re-
lated to early recurrence of AF and were removed from
the model. In the analysis of late recurrence of AF, par-
oxysmal AF, left atrial dimension, and one or more large
PV CSA remained in the model after simultaneous ad-
justment for each the effects of each of these variables.
Adjustment for age and gender did not significantly
affect these results.
We further evaluated the late recurrence of AF by
stratification of study subjects by the presence of one or
more large PV by CSA criteria (Fig. 2), which showed a
significant difference between the groups (p = 0.032).
Multivariate proportional hazards regression identified 3
significant risk factors for late recurrent AF: non-
paroxysmal AF, increasing left atrial dimension, and the
presence of one or more large PV CSA. Stratification of
the study cohort by the number of these risk factors
present identified three risk groups for recurrence
(Fig. 3). Those study subjects with all 3 risk factors had a
high rate of recurrence (100 % by 1 year). Those study
subjects with no risk factors had a very low recurrence
Fig. 1 Product-limit estimates for the probability of recurrent atrial
fibrillation (AF) for the entire cohort, shown for those with early
recurrent AF (recurrence within the first 30 days), late recurrent AF
(recurrence after 30 days), or any recurrent AF
Table 2 Pulmonary vein measurements
Pulmonary Vein N Diameter (cm) CSA (cm2)
Left inferior 58 1.8 ± 0.4 1.7 ± 0.7
Left superior 58 1.7 ± 0.3 1.7 ± 0.5
Left common 13 2.9 ± 0.7 3.4 ± 1.1
Right inferior 71 1.8 ± 0.5 2.3 ± 1.0
Right middle 7 0.9 ± 0.1 0.9 ± 0.2
Right superior 71 2.1 ± 0.6 2.9 ± 1.3
All 278 1.9 ± 0.6 2.2 ± 1.1
CSA = cross-sectional area
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rate (7 % at 1 year). Study subjects with 1 or 2 risk fac-
tors had intermediate recurrence rates.
Discussion
In this prospective study of 71 consecutive patients
undergoing CMR prior to PV isolation, we found that
PV size, left atrial size, and paroxysmal AF are signifi-
cantly and independently related to late recurrent AF
after PV isolation. As PV isolation for the treatment of
AF becomes more common, the appropriate selection of
patients for these procedures becomes more important.
In our study, 100 % of study subjects with non-
paroxysmal AF, increased left atrial size, and one or
more PV with a CSA in the top 10th percentile had re-
current AF at 1 year while only 7 % of study subjects
without these risk factors had late recurrent AF at
1 year.
The PV have a critical role in the pathophysiology of AF.
The PV and left atrium are both derived from the primitive
common PV [12] and therefore have many anatomic and
histologic similarities. Both are smooth-walled structures
that have electrically active myocardium. Approximately
90 % of PVs contain atrial myocardium.[13] Although the
myocardium in the atrium is uniform, myocardium in the
PV is frequently discontinuous and fibrotic. Patients with a
history of AF uniformly have myocardium in the PV and an
increased rate of structural abnormalities. These structural
abnormalities result in abnormal electrical activation with
slow and anisotropic conduction that result in proarrhyth-
mic activity [14] that is directly responsible for the gener-
ation of AF in many patients [2]. Several catheter-based
ablation procedures have been developed to electrically iso-
late the PV from the left atrium for the prevention of AF
with short-term success rates ranging from 65 to 85 % in
patients with paroxysmal AF [2–7].
Recurrent AF after these procedures has generally
been attributed to recovery of electrical function after
the procedure.[8, 9] Larger PV may be at greater risk for
electrical reconnection for three reasons. First, larger PV
may be more difficult to isolate. Second, a larger perim-
eter may provide more opportunity for electrical recon-
nection to take place. Finally, larger PV may have a
higher rate of histological and electrophysiological ab-
normalities that predispose to electrical reconnection.
For these reasons, we hypothesized that patients with
large PV would be at higher risk for electrical reconnec-
tion and thus more recurrent AF after PV isolation. We
found that patients with one or more PV in the top 10th
percentile for CSA were at increased risk of late recur-
rent AF.
Paroxysmal AF has been previously described as pre-
dicting better outcome after PV isolation compared to
persistent or permanent AF. [15–19] We also found that
non-paroxysmal AF is independently associated with
more recurrent AF. This may be due to left atrial re-
modeling due to permanent or persistent AF that may
produce additional triggers for AF in addition to the PV.
Left atrial size has been previously reported to predict
increased rates of recurrent AF, independent of other
predictors, [7, 20, 21] a finding that was confirmed in
our cohort. A prior study found that left atrial size was a
more closely correlated with recurrent AF independent
of PV size [21]. We found that both left atrial size and
PV size were independently associated with late recur-
rent AF. This difference may be due to different methods
Table 3 Prognostic value of pulmonary vein size for the prediction of recurrent atrial fibrillation
Early Recurrent AF Late Recurrent AF
Pulmonary Vein Measure Boundary* N† HR (95 %) p HR (95 % CI) p
Diameter
95th percentile 3.0 cm 8 (11 %) 1.88 (0.77 – 4.56) 0.165 1.28 (0.44 – 3.70) 0.653
90th percentile 2.7 cm 21 (30 %) 1.98 (0.99 – 3.96) 0.053 1.47 (0.67 – 3.21) 0.335
85th percentile 2.4 cm 31 (44 %) 1.87 (0.94 – 3.75) 0.075 1.33 (0.62 – 2.85) 0.464
Cross-sectional area
95th percentile 4.61 cm2 12 (17 %) 2.28 (1.05 – 4.95) 0.037 2.51 (1.05 – 6.00) 0.039
90th percentile 3.71 cm2 20 (28 %) 1.94 (0.96 – 3.91) 0.064 2.25 (1.04 – 4.88) 0.039
85th percentile 3.25 cm2 30 (42 %) 1.52 (0.77 – 3.01) 0.232 1.98 (0.92 – 4.24) 0.079
*The boundary value marks the percentile boundary for all pulmonary veins individually
† N represents the number of study subjects with at least one pulmonary vein measured ≥ boundary value
Table 4 Distribution of large pulmonary veins
Pulmonary Vein N Large Diameter(≥2.7 cm) Large CSA(≥3.71 cm2)
Left inferior 58 1 (2 %) 2 (3 %)
Left superior 58 0 (0 %) 0 (0 %)
Left common 13 6 (46 %) 5 (38 %)
Right inferior 71 4 (6 %) 5 (7 %)
Right middle 7 0 (0 %) 0 (0 %)
Right superior 71 17 (24 %) 15 (21 %)
Large pulmonary veins (PV) were defined as PV in the top 10th percentile for
each measure of PV size. The percentage of large PV at each position
compared to the total number of PV at that position is reported.
CSA = cross-sectional area
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used to measure of left atrial and PV size in the prior
report.
Left atrial fibrosis has also been described as a pre-
dictor of recurrent AF after PV isolation [22]. We did
not routinely obtain pre-ablation late gadolinium en-
hanced images in this cohort. Prediction of recurrent AF
based on the size of the PV appears to compare favor-
ably to prediction based on fibrosis, but assessing both
PV size and left atrial fibrosis in patients where both are
measured would be required to provide an accurate
comparison of predictive accuracy.
We found no other significant relationships of late re-
current AF with any other clinical or anatomic factors. Al-
though advancing age [16], diabetes[23], and the presence
of mitral regurgitation [19] have been previously reported
as associated with recurrent AF, we found no such relation-
ships. This may be due to the relatively small sample size of
this study.
We also examined early recurrence of AF in our data-
set and found that male gender, paroxysmal AF, LV cav-
ity size, left atrial size and the presence of one or more
large PV were all associated with early recurrence of AF.
With multivariate analysis, male gender, paroxysmal AF
and LV cavity size remained significantly associated with
early recurrence of AF. Male gender [24] and left atrial
size [25] have previously been reported to have an asso-
ciation with early recurrent AF. Although prior studies
have found a variable relationship of early recurrent AF
with late recurrent AF [24–26], we found a significant
relationship between the two. The variable findings may
Table 5 Multivariate proportional hazards regression for the recurrence of atrial fibrillation
First Iteration Second Iteration Third Iteration
HR (95 % CI) p HR (95 % CI) p HR (95 % CI) p
Early recurrent AF
Men 3.31 (0.93 – 11.8) 0.065 3.35 (0.94 – 11.97) 0.063 4.06 (1.17 – 14.04) 0.027
Paroxysmal AF 0.47 (0.22 – 1.00) 0.049 0.44 (0.21 – 0.90) 0.025 0.46 (0.23 – 0.95) 0.036
LV end diastolic volume* 0.87 (0.77 – 0.97) 0.014 0.86 (0.77 – 0.97) 0.011 0.86 (0.77 – 0.97) 0.014
Left atrial dimension 1.14 (0.73 – 1.76) 0.573 Removed Removed
One or more large PV CSA 1.72 (0.83 – 3.60) 0.148 1.79 (0.86 – 3.69) 0.118 Removed
Late recurrent AF
Paroxysmal AF 0.47 (0.20 – 1.11) 0.086
Left atrial dimension 1.78 (1.08 – 2.93) 0.023
One or more large PV CSA 2.07 (0.95 – 4.52) 0.069
AF = atrial fibrillation, CI = confidence interval, CSA = cross-sectional area, HR = hazard ratio, LV = left ventricle, PV = pulmonary vein.
* The hazard ratio is reported for a 10 unit change
Fig. 2 Product-limit estimates for the probability of late recurrent
atrial fibrillation stratified by the presence of one or more PV with a
cross-sectional area (CSA) ≥3.7 cm2. The presence of one or more PV
with a cross-sectional area (CSA) ≥3.7 cm2 was associated with more
late recurrent AF (p = 0.032)
Fig. 3 Product-limit estimates for the probability of late recurrent
atrial fibrillation (AF) stratified by the number of risk factors present.
Risk factors for late recurrent AF were non-paroxysmal AF, left atrial
dimension≥ 5.5 cm, and the presence of one or more PV with a
cross-sectional area (CSA) ≥3.7 cm2. The presence of more risk
factors was associated with more late recurrent AF (p = 0.001)
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be due to different definitions of early compared to late
recurrent AF.
We rigorously screened our study cohort for symp-
tomatic or asymptomatic AF using both a 2 week trans-
telephonic event recorder and 24 h Holter monitor at
each follow-up interval as well as additional monitoring
for patients with symptoms. All patients with any recur-
rent AF were deemed a treatment failure even if sinus
rhythm was later restored. As a result, our rate of late
recurrent AF of 41 % at 1 year is higher than that re-
ported by other investigators [2–7].
Conclusions
Among patients referred for their initial PV isolation, the
presence of one or more large PV CSA, non-paroxysmal
AF, and increased left atrial size were independent predic-
tors of late recurrent AF after PV isolation. Stratification by
the number of these factors present identified three risk
groups. Patients with all three risk factors had a very high
rate of recurrent AF. Patients with no risk factors had a
very low rate of recurrent AF. The remaining patients had
an intermediate rate of recurrent AF. These results suggest
that determination of PV size prior to PV isolation may pre-
dict procedural success and identify patients for whom the
procedure is unlikely to result in long-term success.
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